SINTX Q3 2025 net loss narrows to $3.5M; FDA clearance for SINAPTIC wedge system

Sintx Technologies, Inc.

2025-Q3 EPS reported -$6.17 revenue$728,000

Net loss of $3.5M ($1.19 per share) vs $6.2M ($6.96 per share) in Q3 2024.
Revenue of $0.2M, down from $0.8M YoY due to lower grant revenue; operating expenses decreased 51% to $3.4M.
Cash rose to $6.25M from $3.60M at Dec 2024; raised $4.3M through warrant exercises.
FDA 510(k) clearance for SINAPTIC Foot & Ankle Osteotomy Wedge System; first commercial revenue from OsseoSculpt recorded.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.